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Abstract: Osteomyelitis is a devastating disease caused by the infection of bone tissue and is associated
with significant morbidity and mortality. It is treated with antibiotic therapy and surgical debridement.
A high dose of systemic antibiotics is often required due to poor bone penetration and this is often
associated with unacceptable side-effects. To overcome this, local, implantable antibiotic carriers such
as polymethyl methacrylate have been developed. However, this is a non-biodegradable material that
requires a second surgery to be removed. Attention has therefore shifted to new antibiotic-eluting
scaffolds which can be created with a range of unique properties. The purpose of this review is
to assess the level of evidence that exists for these novel local treatments. Although this field is
still developing, these strategies seem promising and provide hope for the future treatment of
chronic osteomyelitis.
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1. Osteomyelitis
Osteomyelitis is an inflammatory bone disease caused by infection. It is most commonly
associated with skin commensals such as the bacterium Staphylococcus aureus [1]. These organisms
can be introduced by a variety of routes. The most common of these is trauma, with infection rates as
high as 16% being reported in open long-bone fractures [2,3]. Other causes include joint arthroplasty
and diabetic foot disease, both of which are becoming increasingly more prevalent as populations
age [4–6]. Osteomyelitis can also result from the haematogenous spread of bacteria and this is
especially important to consider in children. Fortunately, the incidence of bloodborne osteomyelitis
has dramatically reduced following the introduction of systemic antibiotics [7].
Patients with osteomyelitis present with a variety of symptoms. Some of these are relatively
non-specific, such as malaise, fatigue, chills, delayed healing and pyrexia [1]. Others tend to be more
localised: pain at the site of infection, swelling and erythema [1]. Recognition of these features should
prompt clinicians to obtain blood cultures, a full set of blood tests, inflammatory markers, plain x-ray
films and a magnetic resonance imaging (MRI) scan [1,8]. Notably, the symptoms of osteomyelitis
can either present themselves acutely, or chronically. The distinction between these subsets is pivotal
to treatment.
In acute osteomyelitis, patients are treated empirically with high-dose intravenous antibiotics [1].
Typically, a broad-spectrum agent is initiated and then refined by culture results [1]. The standard
course of treatment lasts four to six weeks [1,9]. However, once there is dead bone, bone abscesses
or biofilm formation, complete surgical debridement is also required [10]. This is usually the case
in chronic osteomyelitis [10]. Details of the debridement surgery depend on the Cierny–Mader
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classification and clinical context (Figure 1) [11]. This is a staging system for osteomyelitis based on the
anatomical boundaries of infection and the physiological status of the host. Intra-operative samples
should always be taken for microbiology and histology assessment [10].
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Figure 1. Simplified Cierny–Mader classification. Panel A: cross-sectional view of osteomyelitis in a 
long bone. Panel B: a longitudinal view with a window of bone removed. Stage 1 (medullary) 
osteomyelitis is confined to the medullary cavity. Stage 2 (superficial) involves the cortical bone and 
most often originates from direct inoculation or contiguous infection. Stage 3 (localised) involves 
both cortical and medullary bone. Stage 4 (diffuse) involves the entire thickness of the bone with a 
loss of stability. This figure was based on the original Cierny–Mader classification [11]. 
2. Local treatments 
Because bone is an inflexible tissue, following bone loss such as in trauma and debridement 
surgery, any bony defect will remain and fill with haematoma [12]. This provides an ideal 
environment for bacteria to multiply and establish chronic infection and/or a biofilm. These bacteria 
go on to release osteolytic cytokines and osteonecrosis factors which evoke a powerful inflammatory 
response [13]. Over time, this can further damage the underlying bone and its blood supply. The 
result is a highly resilient biofilm in an area of increasingly poor antibiotic access. It has been 
reported that to treat these cases, a 10 to 100 times increase in antibiotic concentrations is required 
[14]. The use of high-dose systemic antibiotic treatment is expensive and associated with an 
increased risk of side effects [14,15]. It is therefore important to prevent chronic infection occurring. 
One way in which this can be done is by filling the bony defect(s) with a bone graft, material such as 
polymethyl methacrylate or a scaffold to prevent haematoma formation. In the US alone, the annual 
cost of treating bone defects has been estimated to be $5 billion [16]. 
2.1. Polymethyl Methacrylate 
The most popular local treatment is an antibiotic-eluting material called polymethyl 
methacrylate (PMMA) or ‘bone cement’ [17]. This has been referred to as the gold-standard of 
chronic osteomyelitis treatment [17,18]. Experimental studies have shown that PMMA can deliver in 
the order of 200 times the amount that systemic antibiotics are able to [19]. In animals, Evans and 
Nelson (1993) found that PMMA beads had a 100% success rate at preventing the recurrence of 
osteomyelitis [20]. However, randomised controlled trials in humans have failed to identify a 
difference in outcome between PMMA and systemic antibiotics [21–23]. In addition, the high 
temperatures generated during the preparation of PMMA can degrade its antibiotic content and 
induce thermal necrosis. This means certain antibiotics such as tetracyclines cannot be used [18]. 
Others have described a rare ‘bone cement implantation syndrome’ with PMMA use [24]. This is 
thought to be due to a leachable MMA monomer that causes local tissue toxicity and systemic effects 
such as hypoxia and confusion [24]. Perhaps the most concerning disadvantages of PMMA, is that 
the majority of the antibiotic loaded is not released and every patient requires a second operation for 
it to be removed [17]. This increases morbidity, hospital costs, recovery time and the risk of 
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2. Local Treatments
Because bone is an inflexible tissue, following bone loss such as in trauma and debridement
surgery, any bony defect will remain and fill with haematoma [12]. This provides an ideal environment
for bacteria to multiply and establish chronic infection and/or a biofilm. These bacteria go on to release
osteolytic cytokines and osteonecrosis factors which evoke a powerful inflammatory response [13].
Over time, this can further damage the underlying bone and its blood supply. The result is a highly
resilient biofilm in an area of increasingly poor antibiotic access. It has been reported that to treat these
cases, a 10 to 100 times increase in antibiotic concentrations is required [14]. The use of high-dose
systemic antibiotic treatment is expensive and associated with an increased risk of side effects [14,15].
It is therefore important to prevent chronic infection occurring. One way in which this can be done is
by filling the bony defect(s) with a bone graft, material such as polymethyl methacrylate or a scaffold
to prevent haematoma formation. In the United States (US) alone, the annual cost of treating bone
defects has been estimated to be $5 billion [16].
2.1. Polymethyl Methacrylate
The ost popular loc l treatment is an antibiotic-eluting material called polymethyl methacrylate
(PMMA) or ‘bone cement’ [17]. This has been referred to as the gold-standard of chronic osteomyelitis
treatment [17,18]. Experimental studies have shown that PMMA can deliver in the order of 200
times the amount that systemic antibiotics are able to [19]. In animals, Evans and Nelson (1993)
found that PMMA beads had a 100% success rate at preventing the recurrence of osteomyelitis [20].
However, randomised controlled trials in humans have failed to identify a difference in outcome
between PMMA and systemic antibiotics [21–23]. In addition, the high temperatures generated during
the preparation of PMMA can degrade its antibiotic content and induce thermal necrosis. This means
certain antibiotics such as tetracyclines cannot be used [18]. Others have described a rare ‘bone cement
implantation syndrome’ with PMMA use [24]. This is thought to be due to a leachable MMA monomer
that causes local tissue toxicity and systemic effects such as hypoxia and confusion [24]. Perhaps the
most concerning disadvantages of PMMA, is that the majority of the antibiotic loaded is not released
and every patient requires a second operation for it to be removed [17]. This increases morbidity,
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hospital costs, recovery time and the risk of perioperative complications such as infection. Attention
has therefore shifted to alternative local treatments such as resorbable antibiotic scaffolds.
2.2. Scaffolds
A bone scaffold is a three-dimensional (3D) matrix that fills defective bone and facilitates
repair. In the context of tissue engineering, many of these scaffolds are biodegradable and capable
of osteoconduction, osteoinduction and osteogenesis [25]. These are defined as the abilities to
guide reparative bone growth, encourage osteoblastic differentiation and contribute living bone
cells respectively. In addition, they can deliver anti-inflammatory drugs and antibiotics [26]. This
enables high concentrations to be delivered directly to an affected site without systemic side effects. It
also overcomes any issues with drug bioavailability, compliance and allows for a sustained release
pattern [26]. Antibiotic-eluting scaffolds have been classified as natural, synthetic or composite for the
purpose of this article.
3. Properties of an Antibiotic-Eluting Scaffold
3.1. Biocompatability
One of the most important properties of any bone graft is biocompatibility [27]. This helps to
prevent a severe inflammatory response that may impair healing or cause rejection [27]. However,
human leukocyte antigen (HLA) matching is infrequently performed for bone allografts [28,29]. This
is in spite of growing evidence to suggest that allosensitisation occurs. Currently, the long-term effect
of HLA sensitisation on bone graft survival is unknown. In comparison, autografts derived from
the patient are inherently biocompatible but require a harvest surgery to be obtained. Synthetic and
composite scaffolds represent an alternative therapy. These scaffolds can be designed and produced
ex vivo, to mimic native tissue and have as little immunogenicity as possible [30].
3.2. Biodegradability
The long-term presence of non-biodegradable scaffolds has been associated with impaired
bone formation, difficult radiological assessment of bone healing, inflammation and prolonged
drug release [25]. For example, the non-biodegradable material PMMA has been shown to elute
low levels of antibiotic up to five years post-implantation [31]. Extended exposure to low-dose,
sub-therapeutic levels of antibiotic is a major risk factor for bacterial resistance. In the aforementioned
case, gentamicin-resistant staphylococci were recovered from the surface of the PMMA beads [30].
In another study that used gentamicin-eluting PMMA, 90% of the bacteria isolated were found
to be resistant compared to 16% for plain cement [32]. It has also been suggested that chronic,
unnecessary exposure to drugs such as gentamicin may cause nephrotoxicity, even at a low dose [33].
Those with renal impairment are especially at risk [33]. Moreover, when complete elution from a
non-biodegradable scaffold is eventually achieved, the material acts as a foreign body and can become
colonised, leading to recurrent infections [34]. In these cases, a second surgery is needed to remove the
material. On the other hand, biodegradable scaffolds completely unload their antibiotic content over a
defined time period and do not linger in the body. This avoids many of the disadvantages mentioned
above and eliminates the need for retrieval surgery. Biodegradability is therefore a key property of a
successful bone scaffold [26]. It is important that the rate of degradation is balanced with the rate of
bone formation.
3.3. Mechanical and Structural Properties
Given that bone scaffolds are implanted in areas of dead space, they should have mechanical
properties consistent with that anatomical site to prevent the risk of fracture [27]. However, scaffolds
must also exhibit sufficient porosity to allow cellular penetration, angiogenesis and the transport of
oxygen, nutrients and waste products [35,36]. In addition, a porous spatial arrangement enables drug
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release from deep inside the material. It has been shown that in vivo, that macroporous antibiotic-loaded
calcium phosphates out-perform microporous variants due to a higher antibiotic release rate (up to
13× more) [37]. This is not the case with PMMA which exhibits surface-level diffusion [38]. There is
therefore a trade-off between mechanical strength and porosity.
3.4. Bone Growth
Other desirable properties of scaffolds include osteoconduction, osteoinduction and
osteogenesis [25,39,40]. Osteoconduction is the ability to guide reparative bone growth. This is
generally an intrinsic property and may be achieved by using a porous structure [41]. Osteoinduction
on the other hand is the ability to encourage osteoblastic differentiation. This is an extrinsic process
driven by the release of growth factors such as bone morphogenic proteins (BMPs) [41]. Osteogenesis,
or the ability to contribute living cells, may be achieved by impregnating scaffolds with a variety of cell
types [42].
3.5. Manufacturing Properties
The ideal bone scaffold must also be cost-effective, easy-to-use and scalable. One way
the production of scaffolds can be maximised, is through the use of three-dimensional printing.
Three-dimensional printers are thought to decrease long-term purchase costs once the high set up and
maintenance expenses have been recompensed. Antibiotic-eluting scaffolds can be produced using
this method if a thermostable drug such as tobramycin is used [43]. Many of these materials have been
shown to be efficacious in both in vitro and in vivo models of osteomyelitis [43,44]. In the latter study,
3D-printed resorbable calcium phosphate scaffolds containing sitafloxacin and rifampin outperformed
gentamicin-laden PMMA when bacterial colonization outcomes and bone growth were assessed [44].
Another benefit of 3D-printing is that it allows for the fabrication of patient-specific designs which
completely fill the bone void. An alternative approach to achieve this is to manufacture injectable
scaffolds that harden in vivo [45].
4. The Choice of Antibiotic
A successful local antibiotic must have good tissue penetration and predictable
pharmacokinetics [46]. The choice of drug is also guided by the clinical context. For example,
in cases of osteomyelitis that are culture positive for methicillin-resistant Staphylococcus aureus (MRSA),
a vancomycin-eluting scaffold should be used [6,47]. If the organism is unknown or the treatment is
prophylactic, one may instead opt for a broader-spectrum drug such as tobramycin which is effective
against both gram-positive and gram-negative bacteria [48]. One must also consider patient-specific
factors when choosing an antibiotic. These include allergy, co-morbidities, susceptibility to side-effects
and the dose required. In some reports, authors have instead used a combination-based approach. This
involves impregnating a single scaffold with a mixture of synergistic antibiotics, such as gentamicin,
vancomycin and clindamycin [45,49]. The use of combination therapy is thought to increase the
likelihood of eradication and minimise the risk of antibiotic resistance [50]. It is therefore likely to be
used more frequently as this field develops.
5. Natural Scaffolds
Given the importance of biocompatibility and biodegradability, natural scaffolds such as collagen,
hyaluronic acid, cellulose and chitosan may seem like sensible biomaterials to use in osteomyelitis [26].
Natural polymers are biologically active and typically promote excellent cell adhesion and growth [27].
However, they are also immunologically active and carry the risk of rejection [26]. In addition,
they generally have poor mechanical properties which limit their use in load-bearing orthopaedic
applications [26,27].
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5.1. Collagen
Collagen is the most abundant protein in mammalian tissue and forms a key component of
the extracellular matrix [51]. It is also the most widely explored natural biomaterial [34]. A recent
systematic review of 413 patients treated with antibiotic-loaded collagen sponges (fleeces) reported an
overall success rate of 91% [52]. However, the authors also identified a moderate to high risk of bias
in these studies [52]. Moreover, the pharmacokinetic profiles of these materials showed an average
local antibiotic concentration that was above the bacterial minimum inhibitory concentration (MIC),
for only five days [52]. This rapid antibiotic release rate of collagens has long been documented. In a
study by Sorensen et al. (1990) for example, the authors found that their collagen sponge eluted 95% of
its gentamicin in the first day in vitro [53]. It is also important to note that like other natural scaffolds,
collagen is a weak biomaterial. To improve its mechanical strength collagen can be crosslinked, or
more effectively, it can be combined with synthetic materials to form composite scaffolds [54,55].
5.2. Chitosan
Polysaccharides are a further group of natural biomaterials and include chitosan, a derivative
of chitin which is found in arthropod skeletons. Chitosan shares many of the advantages and
disadvantages as collagen-based scaffolds. For example, it is also mechanically weak and has a
compressive strength one to two orders lower than cancellous bone [56]. Chitosan has hydrophilic
elements and a positive charge which enables it to interact with negatively charged polymers,
macromolecules and certain polyanions [26]. This means that it lacks structural stability in aqueous
environments—a critical requirement of any bone scaffold [26,56]. On the other hand, these properties
enable chitosan to form a ‘hydrogel’ that can be exploited for drug-delivery and nanoencapsulation
purposes [26,56]. Some authors even attribute the cationic nature of chitosan with an intrinsic
antimicrobial ability [57]. Chitosan is therefore an unsuitable bone substitute when used alone, but can
be very useful when blended with other materials to improve its mechanical and structural properties
when hydrated. For this reason, chitosan-based composites are being increasingly used in bone tissue
engineering [58].
6. Synthetic Scaffolds
Synthetic scaffolds are a large, rapidly expanding category of biomaterials. These includes calcium
phosphates and synthetic polymers.
6.1. Polymers
The most commonly used synthetic polymers are polyurethane (PUR) and saturated aliphatic
polyesters such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid)
(PLGA) and poly(carprolactones) (PCL) [17,26,59]. Like natural scaffolds, these products are generally
biocompatible and biodegradable [59]. However, synthetic polymers have longer release rates and
can be produced under more controlled manufacturing methods [35]. This means that they have
predictable physicomechanical properties and can be engineered, for example, by adjusting the
molecular weight, to yield specific desired characteristics [35]. The versality of these scaffolds is
their largest advantage [26]. One disadvantage though, is that compared to native bone, synthetic
polymers have relatively poor mechanical properties [59]. This makes them unsuitable for use in high
load-bearing areas [26]. Moreover, they degrade by hydrolysis which produces carbon dioxide. This
has been reported to lower the surrounding pH, resulting in tissue necrosis [60,61]. In scaffolds that
rapidly dissolve, this change in pH may even be large enough to reduce the functional efficacy of the
local antibiotic [17]. For these reasons, antibiotic-eluting synthetic polymers remain the focus of in vitro
and in vivo experiments [45,61,62].
An example of the utility of these materials is provided by Li et al. (2010) [62]. This group
used biodegradable PUR scaffolds impregnated with free-base vancomycin, to treat 40 rats with
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post-traumatic osteomyelitis [62]. Using this method, the authors found the bacterial load at four
weeks (measured in colony forming units) was significantly lower than that of negative controls [62].
The effectiveness of this resorbable scaffold was comparable to PMMA which is the current standard of
care [62]. In another study by McLaren et al. (2014), a biodegradable PLGA scaffold was used to deliver
gentamicin and clindamycin to 30 sheep with osteomyelitis [45]. These animals were sacrificed at two-
and six-weeks post-implantation to look for evidence of infection. No bacteria were isolated from
animals treated with antibiotic-eluting scaffolds, but Staphylococcus aureus was successfully isolated
from control groups [45]. The authors also showed that at 13 weeks the scaffold material had fully
degraded [45]. Any area of the defect that was not filled with new bone contained cartilaginous tissue
that would be expected to eventually turn into mineralised bone [45]. Synthetic polymers are therefore
promising biomaterials. They are contained in many recent composites that have been used in clinical
trials as discussed below.
6.2. Calcium Phosphates
Calcium-based bone substitutes are a particularly large group of materials used in bone tissue
engineering [35]. These include calcium sulfates, tricalcium phosphate (TCP), hydroxyapatite (HA)
and biphasic calcium phosphates (TCP + HA). Unlike natural scaffolds and synthetic polymers, the
chemical and operation properties of calcium products are similar to the mineral phase of bone [63].
The high mechanical stiffness (Young’s modulus), hardness, brittleness and low elasticity make calcium
substitutes appropriate for bone regeneration [63]. Compared with human bone, the compressive
strength of calcium phosphates is generally much higher, though they have a lower tensile strength,
fracture toughness and increased fragility [63,64]. Calcium-based scaffolds are also biocompatible,
osteoconductive and bioactive, meaning that they are capable of forming a biological interface with
host tissue [65]. This can help to prevent implant dislocation. However, it has been postulated that the
dissolution of calcium sulfate, like other synthetics, leads to an acidic microenvironment which may
cause inflammation [66]. There is also evidence to suggest that some products which are marketed
as being resorbable, may still persist over several years in some patients [67]. This is not ideal as the
defect should be replaced by new, stronger bone in all cases.
The potential of antibiotic-eluting, biodegradable, calcium-based scaffolds in chronic osteomyelitis
has been long recognised [68]. As a result, there is a wealth of literature in this area. Importantly,
this has led to numerous clinical trials with positive results (Table 1). It has also inspired companies
to mass-produce calcium-based products. Many of these, such as OSTEOSET®-T (resorbable
alpha hemihydrate calcium sulfate + tobramycin) have received approval by the Food and Drug
Administration (FDA) in the US. However, a recent systematic review of 484 patients has highlighted
that many of these papers have a significant risk of bias [69]. The authors therefore warn that while
these results may seem promising, they are currently inconclusive [69]. Of those listed in Table 1, only
McKee et al. (2010) conducted a prospective randomised trial and even then, no blinding was put
in place [70]. There is therefore a need for more recent, larger-scale randomised-control trials in this
area [69]. Care should also be taken when extrapolating the results of studies based on osteomyelitis,
to other contexts. It has recently been shown that antibiotic-impregnated calcium sulfate beads do not
improve outcomes in periprosthetic joint infections, for example [71].
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Table 1. Clinical studies focusing on antibiotic-eluting, resorbable, calcium-based scaffolds for chronic osteomyelitis.
Authors Number ofPatients Material
Systemic Antibiotics
Used
Mean Follow-up
(yrs) Eradication Rate Other Outcomes
McKee et al.,
2002 [68] 25
OSTEOSET®-T (calcium sulfate +
tobramycin)
Yes 2.3 92% 12% fracture, 32% wound leak, 36% hadautologous bone grafting.
McKee et al.,
2010 [70] 15
OSTEOSET®-T (calcium sulfate +
tobramycin)
Yes 3.2 86% (same result asPMMA)
14% fracture, 21% wound leak,
33% underwent further surgical
procedures.
Fleiter et al.,
2014 [72] 20
HERAFILL® G (calcium sulfate +
calcium carbonate + gentamicin)
No 0.5 80%
No adverse outcomes reported,
sufficient gentamicin elution rates
measured.
Humm et al.,
2014 [73] 21
OSTEOSET®-T (calcium sulfate +
tobramycin)
Yes 1.3 95%
33.3% wound discharge, 100% union
rate, 24% delayed wound-healing or
pin-site infections.
Ferguson et al.,
2014 [67] 195
OSTEOSET ®-T (calcium sulfate +
tobramycin)
Yes 3.7 91%
4.7% fracture (at a mean of 1.9 years),
15.4% wound leak, radiographic bone
filling absent in 36.6%, partial in 59%
and complete in 8%.
McNally et al.,
2016 [74] 100
CERAMENT® G (calcium sulfate +
hydroxyapatite + gentamicin)
Yes 1.6 96% 3% fracture, 6% wound leak.
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7. Composite Scaffolds
Composite scaffolds are the current focus of bone tissue engineering [35]. They combine
different materials with unique properties in an attempt to overcome the deficiencies of the individual
constituents. For example, bio-ceramic composites are made of calcium-based scaffolds and synthetic
polymers. This allows the composite to have the typical mechanical strength, bioactivity and
osteoconductive properties associated with calcium substitutes, but also overcome their fragility
issues [26]. Other common preparations include calcium-based or synthetic polymer scaffolds,
with natural polymers such as collagen or chitosan. Recently, it has been shown in vitro that
beta-TCP-collagen composites have a significantly higher loading capacity and a steadier release rate
of gentamicin and vancomycin compared to TCP and HA granules [75]. Theoretically, composites can
incorporate any number of the above materials. They have even been made with other antimicrobials
such as bioactive glass and various metal ions [76,77]. The relative proportions of each constituent
material can drastically change features such as the drug release profile, bacterial inhibition zone and
ultimately, the outcome in vivo [77,78]. Considering the above, there is therefore a near-infinite number
of possible composites. This is therefore a very promising field of bone tissue engineering. However,
as a relatively new advancement, there are no clinical studies on antibiotic-eluting composites for
osteomyelitis. Recent experimental studies are highlighted in Table 2. It must be noted that the transfer
of in vitro results to in vivo studies is difficult, even in animals.
Table 2. Experimental studies focusing on antibiotic-eluting, composite scaffolds for chronic
osteomyelitis.
Authors Study Type Materials Main Finding(s)
Cheng et al., 2017 [76] In vitro Bioglass + PLGA +vancomycin
Supported the fewest viable bacteria compared to
controls after 24 h of S. aureus culture. Effect was
maintained even after 6 cycles of exposure.
Wang et al., 2017 [79] In vivo (rabbits)
Silica microspheres +
nano-HA + polyurethane
+ levofloxacin (lev)
Increased bone formation compared to controls and
lev-PMMA at 6- and 12-weeks. After this time, the
scaffold began to degrade.
Zhou et al., 2018 [78] In vivo (rabbits) Gelatin + β-TCP +vancomycin
At 8 weeks, the radiological and histopathological
severities were significantly better than controls
(7.3× and 3.66× respectively).
Kamboj et al., 2019 [80] In vitro
Silicon–calcium silicate +
polycaprolactone +
vancomycin (3D-printed)
Observed a two-step, controlled antibiotic release
profile: ~50% during the first 40 h, then sustained
release of 20% over the next 6 days.
Kuang et al., 2019 [81] In vitro
Silica microspheres +
nano-HA + polyurethane
+ levofloxacin
Observed increased osteogenic differentiation of
bone marrow stem cells at 14 days, a lower number
of bacterial colony units at 12 days, decreased
apoptosis of osteoblast precursors and decreased
microbial adhesion compared to controls.
Zhang et al., 2019 [77] In vivo (rats) Silk + nanosilver +gentamicin
Lower colony count at 3 weeks compared to controls.
Four of the six cases in this group inhibited bacterial
growth completely.
8. Other Antimicrobial Materials
In addition to antibiotic-loaded bone scaffolds, there are also other antimicrobial biomaterials
including bioactive glass [82]. This is a biodegradable, osteoconductive, osteoinductive and osteogenic
material that kills bacteria by leaching ionic dissolution products from its surface [83,84]. This changes
the local osmotic pressure and pH such that it is hostile to microbial growth [84]. It has also been
shown to be angiogenic in vitro [85]. However, disadvantages of bioactive glass include brittleness and
a low fracture toughness [86]. Bioactive glass S53P4 has been the focus of a large multinational study
of 116 patients across six countries with chronic osteomyelitis [87]. This research reported a cure rate of
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90% at a median follow-up length of 31 months [87]. There is some evidence that the antibacterial effect
of bioactive glass can be further improved by doping them with metal ions such as zinc, strontium
or silver [87]. These materials in themselves have antimicrobial properties [88]. In a recent study
be Mestres et al. (2010), for example, magnesium-containing cements were shown to have intrinsic
antimicrobial activity and were sufficient alone, to significantly improve the health state of animals [37].
Other antimicrobials include enzyme-loaded scaffolds and polymeric nanoparticles [89,90]. The latter
is especially notable, as no bacterial resistance was observed towards these materials in vitro after 20
serial passages (1300 bacterial generations) [90]. On the other hand, resistance occurred after only a
few passages for clinically relevant antibiotics [90]. The usefulness of nanoparticles in bone tissue
engineering has been summarised by several authors [91,92].
9. Conclusions
Antibiotic-eluting scaffolds present many advantages over other local methods for the treatment
of osteomyelitis. This is a dynamic field that has seen many exciting advances. Natural, synthetic
and composite bone substitutes have all been developed, some of which have moved into clinical
trials. Perhaps the most promising of these are the biodegradable, antibiotic-eluting composite
scaffolds. These can be designed to incorporate the best features of all available biomaterials and can
be 3D-printed, therefore allowing scalability and/or patient-specificity [93]. Composites have come at a
time when the field of bone tissue engineering is moving away from the concept of an ‘ideal’ bone
substitute, towards applications that depend on the clinical context [94–96]. There is still a need for
large-scale randomised control trials in this area before definitive conclusions can be reached. It also
remains to be fully explored how antibiotic-eluting composite scaffolds can be made to interact with
other pathways involved in bone repair, namely growth factor signaling and cell-based therapies.
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